Bamberg

• A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ATTAIN-OSA) Ended recruitment
  2024-515905-25-00 5 2025-01-29 Overweight or Obesity
• LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended recruitment
  2022-501419-15-00 5 2023-08-23 Atrial Fibrillation
• Multicenter, prospective, double-blind, randomized, three-armed, placebo-controlled study of long-term therapeutic transfer of encapsulated … Ended recruitment
  2024-517132-22-00 5 2023-01-26 active ulcerative colitis
• A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide i … Ended recruitment
  2023-509859-13-00 5 2022-11-09 Relapsed or Refractory Multiple Myeloma (RRMM)
• This study is to find out about the Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in … Ended recruitment
  2023-505628-67-00 5 2022-10-28 Relapsed and Refractory Follicular Lymphoma
• A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu … Ended recruitment
  2022-500014-26-00 5 2022-06-24 Locally-Advanced unresectable or Metastatic breast cancer (MBC)
• A Combination of Acalabrutinib with R-CHOP in Subjects with previously untreated non-GCB DLBCL Ended recruitment
  2023-509358-72-00 5 2020-11-23 Diffuse large B-cell lymphoma
• Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended recruitment
  2023-510390-33-00 5 2020-10-23 HER2-negative breast cancer patients with high relapse risk after stan
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab. Ended recruitment
  2023-510248-19-00 5 2020-01-21 Eosinophilic Granulomatosis with Polyangiitis (EGPA)
• Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cel … Ended recruitment
  2024-515783-31-00 5 2018-08-24 Newly Diagnosed Multiple Myeloma
• A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis Ended
  2023-510249-79-00 4 2024-09-10 Progressive pulmonary fibrosis (PPF)
• A randomized, multicenter, open-label trial comparing the effectiveness of Inclisiran to bempedoic acid on LDL cholesterol (LDL-C) lowering … Ended
  2024-511076-32-00 6 2024-06-21 Hypercholesterolemia
• Menthacarin® in the treatment of functional gastrointestinal disorders Ended
  2022-501800-92-00 6 2023-05-15 functional gastrointestinal disorders
• Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended
  2022-501063-41-00 5 2023-04-20 Chronic Obstructive Pulmonary Disease (COPD)
• Clinical study to show if Naronapride tablets are safe and efficient for treatment of delayed stomach emptying and to find the optimal dose. Ended
  2023-510195-31-00 4 2023-01-03 Idiopathic or Diabetic Gastroparesis
• A study to find out whether BI 1015550 improves lung function in people with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) Ended
  2024-512803-37-00 5 2022-10-05 Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
• Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of … Ended
  2024-511263-28-00 6 2022-04-08 Hypercholesterolemia
• Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended
  2023-503572-24-00 5 2022-03-02 Chronic Obstructive Pulmonary Disease (COPD)
• A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease (COPD) Ended
  2023-507093-40-00 4 2022-01-27 Chronic Obstructive Pulmonary Disease (COPD)
• The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) Ended
  2023-510175-60-00 5 2021-06-16 Chronic obstructive pulmonary disease (COPD) and Chronic Bronchitis
• A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with S … Ended
  2023-505786-88-00 5 2021-04-25 Severe and inadequately controlled asthma
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV … Ended
  2023-507846-96-00 5 2020-06-19 Type 2 Diabetes Mellitus
• Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent Exace … Ended
  2022-503050-39-00 5 2019-11-12 Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) w

Showing 25–48 of 50 trials